Out to revamp plant-based drug manufacturing, Antheia locks in partnership with synthetic biology…
With supply chain shortages at the forefront of nearly every business in the world right now, whether it be chicken wings or CAR-T cell therapy, synthetic biology upstart Antheia…
Female-Founded Antheia Raises $73 Million to Support Synthetic Biology for Essential Medicines
Synthetic biology startup Antheia raised $73 million in Series B financing to support the company’s efforts to bring its first plant-based medicine to market and support the production of necessary…
Investing in the next wave of biomanufacturing technologies for pharma
The global pandemic has brought pharmaceutical manufacturing to the forefront of America’s public consciousness. Acute drug shortages brought on by COVID-19 have underscored the need for domestic production and more resilient supply chains…
Meet the Team – Our Lab Operations Team
For the final installation in our “Meet the Team” series, we hear from Olivia, Khurram and Vicky, who lead our operations. This team is the key to ensuring Antheia’s labs are running successfully and efficiently…
Scaling synthetic biology as a manufacturing platform
For decades, synthetic biology has promised to make manufacturing more efficient, sustainable, and responsive to sudden changes in supply and demand. It has the potential to create new value across industries by transforming everything from food to pharmaceuticals…
Meet the Team – Our Engineer, Yuki Higa
For the next installation in the “Meet the Team” series, we hear from Yuki Higa, a Process Engineer at Antheia. Read on to learn about Yuki’s fast-paced work in a downstream processing group…
Meet the Team – Our RA, Cat Cleto
We’re excited for the next interview in our “Meet the Team” series! We hear from Cat Cleto, a Fermentation Research Associate, on her path from the world of retail to biotech and what she’s looking forward to over the next year…
Antheia Receives Phase II SBIR Awards to Develop Safer Manufacturing Processes for Painkillers
This NSF Phase II award “A complete bioprocess for medicinal plant opioids” has built upon the early-stage R&D completed under the Phase I award (1621560).
Can This Silicon Valley Startup Bioengineer A Less Addictive Opioid?
Back in 2015, a 40-year-old synthetic biologist named Christina Smolke, along with a small team of researchers at Stanford, made a huge discovery. They proved that a genetically engineered yeast could produce opioid molecules…
Antheia Receives Phase I SBIR Award from the National Institute of Drug Abuse to Make Non-Addict…
The objective of this Phase I SBIR project will be to develop engineered yeast strains that produce high levels of noroxymorphone, the direct precursor for the nal opioids naloxone and naltrexone through whole cell biocatalysis…